^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    EPHA5 (EPH Receptor A5)

    i
    Other names: EPHA5, EPH Receptor A5, TYRO4, EHK1, HEK7, Ephrin Type-A Receptor 5, EPH Homology Kinase 1, Brain-Specific Kinase, EPH-Like Kinase 7, EHK-1, CEK7, EK7, Epididymis Secretory Sperm Binding Protein, Tyrosine-Protein Kinase Receptor EHK-1, Receptor Protein-Tyrosine Kinase HEK7, EPHA5, Hek7, BSK
    2ms
    Ephrin Receptors and Ephrin Ligands in Uveal Melanoma: A Big Data Analysis Using Web Resources. (PubMed, Int J Mol Sci)
    In conclusion, our results highlight that a subset of EPHs and EFNs may be associated with worse clinical outcomes (EPHA4, EPHA5, EPHA7, EPHA8, EPHB2, EFNA2, and EFNB2), and an aggressive histological subtype (EPHA2, EPHA4, EPHA8, EPHB4, EFNA1, EFNA3, EFNA4, and EFNB2). The potential correlation of these genes with clinicopathological parameters of UVM need to be evaluated and validated with bioinformatic and experimental approaches in well-characterized cohorts of UVM patients.
    Journal
    |
    EFNB2 (Ephrin B2) • EPHB2 (EPH Receptor B2) • EPHB4 (EPH receptor B4) • EPHA5 (EPH Receptor A5) • EPHA7 (EPH Receptor A7) • EFNA1 (Ephrin A1) • EFNA4 (Ephrin A4) • EPHA4 (EPH Receptor A4)
    2ms
    Small intestinal SMARCA4-deficient undifferentiated carcinoma with intussusception: A case report. (PubMed, Oncol Lett)
    Next-generation sequencing of the primary small intestinal tumor identified pathogenic mutations in PTEN, TP53, ataxia telangiectasia mutated, ephrin type-A receptor 5 and EGFR p.F997L, suggesting a DNA-repair-deficient genomic background and providing potential targets for future precision therapy. Further research is warranted to determine the molecular mechanisms underlying SMARCA4-DUC, for the development of targeted therapeutic strategies and to improve the understanding of the aggressiveness of SMARCA4-DUC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • EPHA5 (EPH Receptor A5)
    |
    TP53 mutation • EGFR mutation • PTEN mutation
    4ms
    Comparative analysis reveals recurrent molecular alterations in low-risk HPV6 and HPV11-associated squamous cell carcinoma of the uterine cervix and vulva. (PubMed, Mod Pathol)
    We provide evidence that SCCs associated with low-risk HPV are distinct entities, differing from those related to high-risk HPV and more closely resembling HPV-independent neoplasms. Given that low-risk HPV-associated SCCs of the cervix and vulva exhibit unique morphological and molecular features, they should either be described separately within existing classification systems or classified as a distinct new entity.
    Journal
    |
    TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR2 (Fibroblast growth factor receptor 2) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • TERT (Telomerase Reverse Transcriptase) • ASXL1 (ASXL Transcriptional Regulator 1) • ATRX (ATRX Chromatin Remodeler) • TSC2 (TSC complex subunit 2) • NOTCH2 (Notch 2) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • CARD11 (Caspase Recruitment Domain Family Member 11) • NOTCH3 (Notch Receptor 3) • STAG2 (Stromal Antigen 2) • KMT2B (Lysine Methyltransferase 2B) • EPHA5 (EPH Receptor A5) • FNDC1 (Fibronectin Type III Domain Containing 1) • BCORL1 (BCL6 Corepressor Like 1)
    |
    ARID1A mutation • FGFR2 mutation
    5ms
    Analysis of Microarray and Single-Cell RNA-Seq Finds Gene Co-Expression and Tumor Environment Associated with Extracellular Matrix in Epithelial-Mesenchymal Transition in Prostate Cancer. (PubMed, Int J Mol Sci)
    In this study, we aimed to shed light on the molecular characteristics and pathways of DEGs in PCa, as well as to identify possible biomarkers that are important in the development and advancement of this cancer. These insights have important implications for understanding prostate cancer progression and for the development of therapeutic strategies targeting ECM-mediated pathways.
    Journal
    |
    EPHA5 (EPH Receptor A5)
    6ms
    EphA5 Expression Predicts Better Survival Despite an Association with Proliferative Activity in Endometrial Cancer. (PubMed, J Clin Med)
    EphA5 may act as a context-dependent biomarker in EC. Despite its positive correlation with proliferation and negative association with metabolic stress signaling, high EphA5 expression levels were predictive of a favorable prognosis.
    Journal
    |
    EPHA5 (EPH Receptor A5)
    7ms
    First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors. (PubMed, J Clin Invest)
    Preclinical Good Laboratory Practice-compliant toxicology studies in rats and nonhuman primates demonstrated that MBRC-101 is well tolerated, with observed toxicities limited to known MMAE off-target effects. These findings establish EphA5 as a therapeutic target in cancer and support the translational development of MBRC-101 as a promising ADC candidate for clinical evaluation, currently in a first-in-human multicenter investigational trial for patients with advanced solid tumors (ClinicalTrials.gov, NCT06014658).
    Preclinical • Journal
    |
    EPHA5 (EPH Receptor A5)
    |
    MBRC-101
    8ms
    EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway [Retraction]. (PubMed, Cancer Manag Res)
    [This retracts the article DOI: 10.2147/CMAR.S261182.].
    Journal
    |
    EPHA5 (EPH Receptor A5)
    10ms
    EPHA5 promotes cell proliferation and inhibits apoptosis in Follicular Thyroid Cancer via the STAT3 signaling pathway. (PubMed, Oncogenesis)
    Interestingly, the influence of EPHA5 on proliferation and apoptosis was reduced upon combination with SH-4-54. In summary, this study unveils the involvement of the EPHA5-STAT3 signaling pathway in FTC and implies that the function of EPHA5 in FTC may partly depend on the STAT3 signaling pathway.
    Journal
    |
    EPHA5 (EPH Receptor A5)
    1year
    Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=130, Recruiting, MBrace Therapeutics | Phase classification: P1 --> P1/2 | N=90 --> 130 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • EPHA5 (EPH Receptor A5)
    |
    HR positive • HER-2 negative
    |
    MBRC-101
    1year
    Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node. (PubMed, Front Immunol)
    This is the first report on the panorama gene profile of ovarian cancer metastasis to axillary lymph node and we found two novel mutations (BTK pD326E and EPHA5 pD251E). This study unraveled the potential mechanism of genetic mutation for tumor metabolism, drug resistance, and metastasis.
    Journal
    |
    BTK (Bruton Tyrosine Kinase) • EPHA5 (EPH Receptor A5)
    over1year
    EMBRACE: Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (clinicaltrials.gov)
    P3, N=201, Suspended, Academic and Community Cancer Research United | Trial completion date: Dec 2023 --> Oct 2024
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • EPHA5 (EPH Receptor A5)
    |
    paclitaxel • Halaven (eribulin mesylate)
    over1year
    Clinicopathological analysis of gastric adenocarcinoma with elevated serum alpha-fetoprotein and enteroblastic differentiation (PubMed, Zhonghua Zhong Liu Za Zhi)
    TP53 mutation is the most common type of gene mutation. In addition, some cases are accompanied by HER2 amplification and gene rearrangement.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR3 (Fibroblast growth factor receptor 3) • CCNE1 (Cyclin E1) • LRP1B (LDL Receptor Related Protein 1B) • ATRX (ATRX Chromatin Remodeler) • AFP (Alpha-fetoprotein) • CLDN6 (Claudin 6) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • GPC3 (Glypican 3) • IRS2 (Insulin receptor substrate 2) • SOX2 • GNAS (GNAS Complex Locus) • MME (Membrane Metalloendopeptidase) • CDX2 (Caudal Type Homeobox 2) • SALL4 (Spalt Like Transcription Factor 4) • EPHA5 (EPH Receptor A5) • EPHB1 (EPH Receptor B1) • GATA3 (GATA binding protein 3) • EPHA6 (EPH Receptor A6) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4)